Bicara, Zenas outline plans for $180M IPOs amid restored optimism for biotech debuts

Bicara Ther­a­peu­tics and Zenas Bio­Phar­ma are now a step clos­er to kick­ing open a mi­ni-IPO win­dow for drug de­vel­op­ers this fall.

The star­tups out­lined plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.